Navigation Links
Radiopharmaceutical Cardiolite has 15 Percent More Market Share than Myoview for September 2008
Date:11/11/2008

Administration of Astellas's Lexiscan in Patients Increased by 58 Percent From August to September 2008, According To New Data from Arlington Medical Resources

MALVERN, Pa., Nov. 11 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that Lantheus Medical Imaging's Cardiolite has 15 percent more market share than General Electric's Myoview for September 2008. Both Cardiolite and Myoview are administered intravenously as part of the Myocardial Perfusion Imaging Stress Test to highlight areas of the heart. The Myocardial Perfusion Imaging Stress Test is given to help diagnose coronary artery disease.

"Compared to data from our September 2007 audit, Cardiolite use has dropped nine percent. Even so, Cardiolite continues to dominate the radiopharmaceutical market," stated Anna Fisher, analyst at AMR.

The newly released edition of the Myocardial Perfusion Study Monthly Monitor also finds the number of patients who were administered Astellas's Lexiscan (regadenoson) increased 58.5 percent from August 2008 to September 2008. Lexiscan is the newest pharmacologic stress agent on the market--introduced in June 2008--and it is used in patients unable to undergo exercise stress testing.

Why Pharmaceutical and Medical Device Companies Need this Information

The Myocardial Perfusion Study Monthly Monitor enables pharmaceutical and medical device companies to track the number of nuclear myocardial perfusion tests performed in hospital and non-hospital settings. For each study month, this audit provides projections of myocardial perfusion studies performed with each of the various radiopharmaceutical products. Projections are also provided for the number of studies involving pharmacologic stressing with intravenous adenosine, intravenous dipyridamole, intravenous regadenoson and intravenous dobutamine.

About the Myocardial Perfusion
'/>"/>

SOURCE Arlington Medical Resources
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
2. For the First Time this Winter Consumers Have an Electronic Green Solution that Eliminates 99.97 Percent of Indoor Air Pollution
3. Volcano Reports 40 Percent Growth in Quarterly Revenues
4. Healthy bones program reduces hip fractures by 37 percent
5. PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers*
6. Professional Healthcare Ranked Among the Top 25 Percent of Home Health Care Providers in the Country for 2008
7. Growth Rate of U.S. Giving for Health Care Falls More Than 50 Percent in 2007 But Rises Almost Threefold in Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
8. HireRight Named to Deloitte Technology Fast 50 for the Sixth Year in a Row : Attributes Customer Focus and Innovative Screening Solutions to its 230 Percent Revenue Growth
9. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
10. Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets
11. Death rate 70 percent lower at top-rated hospitals: HealthGrades annual hospital quality study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
Breaking Medicine News(10 mins):Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2
... Oct. 6 HealthSouth,Corporation (NYSE: HLS ) tod...zed investor meeting in New York City. Presentatio...T at the Grand Hyatt New York, located at,109 E. 4... -- HealthSouth Overview and Industry...
...6 The United States has,intervened in a lawsuit a...ted false claims to Medicare arising from illegal ...dical equipment (DME) suppliers, the,Justice Depar...ry LLC, Beverly Enterprises Inc., CERES Strategies...
... Developed in collaboration with,Siemens(R), Axis...cing,Revolutionary Breast Surface Imaging and Morp... Dr. Steve Laverson this week in Encinitas, CA.,Th...prietary software. The XS-300(TM) platform photogr...
...ct. 6 Ohio,s academic health care,industry contri..., an,increase of approximately $16.5 billion since...ing one in 12 Ohioans, according to a recent study...n, the report underscores the significant role,Ohi...
... Millions of women suffer with symptoms o...ion economic rescue plan. But the effects of our c...ome making it increasingly difficult for U.S. wome...hout a prescription. , La...
..., Oct. 6 SAP AG (NYSE: SAP ),today announced tha...sident,of the Healthcare industry business unit. I...andrea will help drive SAP,s industry leadership,e...nnual Ambassadors Dinner and the U.S.-EU eHealth C...
Other Medicine News:Health News:HealthSouth to Hold Investor Meeting November 10, 2008 2Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Plan Your Breasts in 3-D 2Health News:Academic Medicine Means Business for Ohio: $37.2 Billion Economic Impact for the State 2Health News:Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines 2Health News:Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines 3Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 2Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 3
(Date:12/4/2009)TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced the three grand prize winners of Bayer,s "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winn
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) announced today that the US Patent and Trademark Office has allowed its patent application o
(Date:12/4/2009)RARITAN, N.J., Dec. 4 Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Fastrack Clients Realize Substantial Benefits from On Line Training 60134 1Fastrack Clients Realize Substantial Benefits from On Line Training 60134 2Ross University School of Medicine Recognized for Commitment to Public Service and Civic Leadership 60132 1Ross University School of Medicine Recognized for Commitment to Public Service and Civic Leadership 60132 2An Alternative To Adderall 3F 60130 1An Alternative To Adderall 3F 60130 2An Alternative To Adderall 3F 60130 3
...ll Doses of VYVANSE Studied Demonstrated Significa... of Daily Treatment, BOSTON, Oct. 25 Shire plc (...cialty biopharmaceutical company, today,announced ...lts with,Attention Deficit Hyperactivity Disorder ...D symptom control within one week of treatment wit...
...ignificant Survival Advantage Shown in Lung Cancer...Nasdaq: ENMD ), a clinical-stage pharmaceutical c...f cancer and inflammatory diseases, today,announce...tic results for,its antimitotic agent, ENMD-1198, ...ts. The data were presented at the AACR-NCI-EORTC,...
Other Medicine Technology:Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting 2Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting 3Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting 4Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting 5Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting 6EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198 2EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198 3
... Clear Plus™ Uncuffed Endotracheal Tube w. F...et inside. Sterile, Single use. A quality Rusch en... is ready to use saving you time and storage space...ate smooth withdrawal. It is designed with a soft ...
Slick Set® Uncuffed
Cuffed Nasoral Magill
...ubber tube with Murphy eye. Laser resistant foam s...uffs (One inside other) 40cm (16") long, Single Us...access and optimum visibility within the operating...he tube shaft has a special laser-guard of approx....
Medicine Products: